All RA patients were under immunosuppressive therapy: 32% were receiving only conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), 20.1% Tumour Necrosis Factor (TNF)-α inhibitors, 19.6% Cytotoxic T-Lymphocyte Antigen 4-Immunoglobulin (CTLA4-Ig), 9.3% anti-IL6R monoclonal antibody, 25.3% Janus kinase (JAK) inhibitors, 5.7% anti-CD20 monoclonal antibody and 17.1% glucocorticoids (GCs). The gene discussed is CTLA4; the disease is rheumatoid arthritis.